Drug Delivery Disposition and Dynamics
Latest news from D4
A Monash-led Phase 1 clinical trial to assess the safety and performance of a novel oxytocin inhaler is now a step closer to completion with the conclusion of subject recruitment conducted by Nucleus Network located at the Alfred Hospital.
Professor Ben Boyd is one of eight AAPS members selected for “elevation to Fellow status in recognition of their professional excellence and sustained superior impact in fields relevant to AAPS’ mission."
The breakthrough can improve outcomes in one of the world’s newest forms of cancer immunotherapies, CAR-T cell therapy.
The Monash-Moderna Quantitative Pharmacology Accelerator (MMQPA) is a five-year program which aims to drive advancements in mRNA medicines, including therapeutics and vaccines.
Australia will establish its first Drug Target Identification Platform to provide target identification services to the Australian drug discovery community.
The Glyph technology was initially developed by Professor Chris Porter and his team at MIPS and exclusively licensed to PureTech Health in 2017.
A Phase 1 clinical trial led by Monash University to assess the safety and performance of a novel oxytocin inhaler in healthy, non-pregnant female volunteers has commenced in Melbourne.
MIPS has welcomed representatives from South Africa’s Afrigen Biologics and the South African Medical Research Council, along with mRNA Victoria, to meet with MIPS mRNA researchers who are working to identify and select promising therapeutic